Idera Pharma Offers Preclinical Data Showing Enhanced Systemic Anti-Tumor Activity from Combo Treatment with Intra-tumoral IMO-2125, IDO-1 Inhibitor at AACR
April 19, 2016 at 07:34 AM EDT
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA ...
